Inhalation & Nasal Spray Generic Drugs 2013

Inhalation & Nasal Spray Generic Drugs 2013

Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The t Spiriva (tiotropium bromide) achieved sales of US$4.6 billion. In third place was AstraZeneca’s Symbicort (budesonide+formoterol), with sales of US$3.2 billion High revenue originator drugs undoubtedly attract interest from prospective generic competitors. Unlike the oral generics market, however, where numerous companies While there have been some generic approvals in Europe, the US market for generic MDIs has been virtually non-existent since the CFC ban was enforced at the end of GSK’s Advair may be developed for the US market; it has also made it possible for companies to hold pre-ANDA meetings, to help to resolve complex issues pri Teva recently suggested that the first bioequivalent Advair generic is unlikely to be available before 2018. In the meantime, Teva is developing a proprietary combinatio of Advair in development, it will be interesting to see how long it will be before any of these reach the market, and whether or not they will be able to gain significant ma table Of Content

foreword

executive Summary

respiratory Drugs Market market Leaders generics challenges For Generic Developers critical Path Opportunities For Generic Drugs In The Us fda Publishes Draft Guidance For Mdis

asthma & Copd market Overview asthma copd market Leaders new Products To Watch generic Competition flixotide/flovent (fluticasone Propionate) mode Of Action approvals patents generic Company Activity market Outlook seretide/advair (fluticasone Propionate+ Salmeterol Xinafoate) mode Of Action approvals patents fda Draft Guidance For Fluticasone Propionate+salmeterol Xinafoate generic Company Activity teva mylan sandoz cipla market Outlook serevent (salmeterol Xinafoate) mode Of Action approvals patents generic Company Activity market Outlook...